Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Items 501–600 of 796
Reiman, E. M., & Langbaum, J. B. S. (2009) · Imaging the Aging Brain · doi:10.1093/acprof:oso/9780195328875.003.0020 · Cited by 16
Shoghi, K. I., Barrio, J. R., Kepe, V., & Huang, S. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-006-0037-4 · Cited by 17
Self-citationLithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer’s Disease
Gherardelli, C., Cisternas, P., & Inestrosa, N. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158733 · Cited by 16
Animal model of posterior cingulate cortex hypometabolism implicated in amnestic MCI and AD
Riha, P. D., Rojas, J. C., Colorado, R. A., & Gonzalez-Lima, F. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.01.011 · Cited by 17
“…in PCC has also been found in asymptomatic subjects at genetic risk for AD, such as subjects homozygotic for the E4 allele of the apolipoprotein E gene (Reiman et al., 1996; Small et al., 2000), and in patients with amnestic mild cognitive impairment (MCI) who later develop AD (Mosconi, 2005).”
BackgroundMolecular Imaging of Biological Processes with PET: Evaluating Biologic Bases of Cerebral Function
Silverman, D. H. S., & Melega, W. P. (2004) · Springer eBooks · doi:10.1007/978-0-387-22529-6_7 · Cited by 18
Self-citationAssociations between handedness and executive function in upper-middle-aged people
Hatta, T. (2017) · Laterality Asymmetries of Body Brain and Cognition · doi:10.1080/1357650x.2017.1358273 · Cited by 16
“Small et al. (2000) reported that in a PET study, they found that the size drop of over 2 years in cognitive performance was significantly correlated with metabolic rates in the right inferior parietal lobule in the APO-4-positive group but not in the APOE-4-negative group.”
BackgroundTsai, C., Sun, H., Kuo, Y., & Pai, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101639 · Cited by 16
“In addition, Small et al. (2000) demonstrated that a single copy of the ApoE-4 allele is also associated with lower cerebral cortical metabolism (e.g., the parietal, temporal, and posterior cingulate areas) [4], which could predict cognitive decline after 2 years of longitudinal follow-up since…”
BackgroundInfluentialWang, X., Chen, H., Yan, J., Nho, K. T., Risacher, S. L., Saykin, A. J., Shen, L., Huang, H., & Initiative, A. D. N. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty557 · Cited by 15
The concept of FDG-PET endophenotype in Alzheimer’s disease
During, E., Osorio, R. S., Elahi, F. M., Mosconi, L., & de Leon, M. J. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0633-1 · Cited by 14
“It also appears to have a higher accuracy than PIBPET [43] (85 and 75%, respectively) in the distinction of normal versus mild cognitive impairment (MCI), a prodromal stage of dementia [44, 45] characterized by milder abnormalities in the same areas except for frontal cortex [46–53].”
InfluentialLiu, M., Lian, C., & Shen, D. G. (2019) · Intelligent systems reference library · doi:10.1007/978-3-030-32606-7_8 · Cited by 14
de Souza, A. S., de Oliveira‐Souza, R., Moll, J., Tovar-Moll, F. F., Andreiuolo, P. Â., & Bottino, C. M. C. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000334656 · Cited by 16
Brain-imaging surrogate markers for detection and prevention of age-related memory loss
Small, G. W. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0005-7 · Cited by 14
Self-citationErcoli, L., Siddarth, P., Harrison, T., Jimenez, E. E., & Jarvik, L. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281866 · Cited by 11
“The 24 persons in the comparison group were drawn from 2 larger longitudinal studies on predictors of cognitive decline in older adults.(4,6) Subjects had been recruited through advertisements and physician referrals for middle-aged and older healthy volunteers with or without a family history of dementia and/or memor…”
BackgroundSelf-citationSoluble Oligomers of the Amyloid β-Protein: Impair Synaptic Plasticity and Behavior
Selkoe, D. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-76330-7_8 · Cited by 18
A Metabolic Imaging Severity Rating Scale for the Assessment of Cognitive Impairment
Newberg, A. B., Cotter, A., Udeshi, M., Alavi, A. A., & Clark, C. (2003) · Clinical Nuclear Medicine · doi:10.1097/00003072-200307000-00006 · Cited by 14
Biological Markers for Alzheimer's Disease
Tapiola, T. (2001) · Cited by 28
In-vivoandin-vitrotechniques used to investigate Alzheimer's disease
Tiwari, V., Solanki, V., & Tiwari, M. (2015) · Frontiers in Life Science · doi:10.1080/21553769.2015.1044129 · Cited by 15
The Combined Effect of APOE and BDNF Val66Met Polymorphisms on Spatial Navigation in Older Adults
Laczó, J., Čechová, K., Pařízková, M., Lerch, O., Andel, R., Maťoška, V., Kaplan, V., Matušková, V., Nedelská, Z., Vyhnálek, M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200615 · Cited by 14
“[22, 88] but their structural changes related to the”
BackgroundTsai, C., Erickson, K. I., Sun, H., Kuo, Y., & Pai, M. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113268 · Cited by 14
Piquet, J., Toussay, X., Hepp, R., Lerchundi, R., Douce, J. L., Faivre, É., Guiot, E., Bonvento, G., & Cauli, B. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00216 · Cited by 13
“The visualization by 18-fluoro-2-deoxy-Dglucose positron emission tomography of a decreased cerebral glucose utilization occurring in specific brain regions is one of the earliest functional signs of AD (Small et al., 2000; Dubois et al., 2016).”
MethodThe consequences of neurodegenerative disease on neuron-astrocyte metabolic and redox interactions
Jiwaji, Z., & Hardingham, G. E. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106255 · Cited by 14
Abghari, M., Vu, J. T. C. M., Eckberg, N., Aldana, B. I., & Kohlmeier, K. A. (2023) · Biomolecules · doi:10.3390/biom13101461 · Cited by 12
Polygenic Risk Score for Alzheimer’s Disease Is Associated With Ch4 Volume in Normal Subjects
Wang, T., Han, Z., Yang, Y., Tian, R., Zhou, W., Ren, P., Wang, P., Zong, J., Hu, Y., & Jiang, Q. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00519 · Cited by 13
“Many studies investigated AD-associated variants in biomarker measurements among healthy subjects using polygenic score approach (Small et al., 2000; Reiman et al., 2004; Filippini et al., 2009; Sheline et al., 2010; Sabuncu et al., 2012; Mormino et al., 2016).”
BackgroundDay, M., Chandran, P., Luo, F. R., Rustay, N. R., Markosyan, S., LeBlond, D. J., & Fox, G. B. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.05.032 · Cited by 13
Albin, R. L., Koeppe, R. A., Burke, J. F., Giordani, B., Kilbourn, M. R., Gilman, S., & Frey, K. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.34 · Cited by 13
“progression from MCI, and predicting the rate of progression of dementia.(9-26) Fludeoxyglucose F18–PET identifies char-”
BackgroundPositron Emission Tomography Diagnosis of Alzheimer's Disease
Coleman, R. E. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.09.003 · Cited by 13
Huang, C. C., Mattis, P. J., & Julin, P. (2007) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2007.05.003 · Cited by 14
Rice, F. J., Abraham, R., Rudrasingham, V., Owen, M. J., & Williams, J. H. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.808 · Cited by 13
Thompson, P. M., Mega, M. S., & Toga, A. W. (2002) · Elsevier eBooks · doi:10.1016/b978-012693019-1/50030-7 · Cited by 12
Self-citationKumar, A. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00001 · Cited by 11
Molecular basis of memory loss in the Tg2576 mouse model of Alzheimer's disease
Ashe, K. H. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s314 · Cited by 11
“Intriguingly, asymptomatic individuals at risk genetically for Alzheimer’s disease have evidence of brain dysfunction in functional magnetic resonance imaging and positron emission tomography studies [2,13], suggesting that there may be a latent phase of Alzheimer’s disease.”
Fowler, J. S., Volkow, N. D., Wang, G., & Ding, Y. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.01.002 · Cited by 12
Matura, S., Köhler, J., Reif, A., Fußer, F., Karakaya, T., Scheibe, M., Ehret, F., Hartmann, D., Kang, J., Mayer, C., et al. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.49 · Cited by 11
“…state glucose metabolism in the PCC of patients with early AD (Buckner et al., 2005), MCI (Ishii et al., 2003) and also in cognitively intact (Reiman et al., 1996; Small et al., 2000; Reiman et al., 2004; Chen et al., 2012) elderly persons, possibly reflecting synaptic decline in this region.”
BackgroundPeroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations
Espinosa-Jiménez, T., Busquets, O., Cano, A. C., Sánchez‐López, E., Verdaguer, E., Parcerisas, A., Olloquequi, J., Auladell, C., Folch, J., Wahli, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.902047 · Cited by 11
“In fact, AD is considered as type 3 diabetes (Small et al., 2000; Leszek et al., 2017).”
BackgroundSCN1A Affects Brain Structure and the Neural Activity of the Aging Brain
Meier, S., Demirakça, T., Brusniak, W., Wolf, I., Liebsch, K., Tunc‐Skarka, N., Nieratschker, V., Witt, S. H., Matthäus, F., Ende, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.017 · Cited by 12
The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism
Lyons, C. E., Tudorascu, D. L., Snitz, B. E., Price, J. C., Aizenstein, H. J., López, O. L., Lopresti, B. J., Laymon, C. M., Minhas, D. S., Kamboh, M. I., et al. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.03.018 · Cited by 10
Ikeuchi, T., Yano, Y., Sato, W., Morikawa, F., Toru, S., Nishimura, C., MIYAZAWA, N., Kuroha, Y., Koike, R., Tanaka, S., et al. (2022) · Nutrients · doi:10.3390/nu14030637 · Cited by 10
“According to previous studies [21,22], we defined participants with ε4 allele as the APOE-positive group and those without ε4 allele as the APOE-negative group.”
MethodPotential Value of Quantitative Analysis of Cerebral PET in Early Cognitive Decline
Patterson, J. C., Lilien, D. L., Takalkar, A. M., Kelley, R. E., & Minagar, A. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508323447 · Cited by 10
“Recent reports suggest that it is possible to detect brain metabolic changes using PET across groups of premorbid patients, who have not yet developed MCI, before subjective symptoms or neuropsychological impairment occurs.(7,8) These studies imply that PET scanning using FDG may be a sensitive measure for detection o…”
BackgroundDeme, P., Rojas, C. J., Slusher, B. S., Rais, R., Afghah, Z., Geiger, J. D., & Haughey, N. J. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113181 · Cited by 10
Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience
Kumar, A., Ajilore, O., Kepe, V., Barrio, J. R., & Small, G. W. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1941 · Cited by 11
“Our studies (Small et al., 1995, 2000), confirmed by others (Reiman et al., 1996, 2001), indicate lower regional brain metabolism in middle-aged and older persons with a genetic risk (APOE-4), lending further support for a prolonged presymptomatic AD stage.”
ResultSelf-citationLehéricy, S., Delmaire, C., Galanaud, D., & Dormont, D. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.04.029 · Cited by 11
Pomara, N., Facelle, T. M., Roth, A. E., Willoughby, L. M., Greenblatt, D. J., & Sidtis, J. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0336-0 · Cited by 10
Increased CSF cortisol in AD is a function of APOE genotype
Sass, J. O., Heinz‐Erian, P., & Högler, W. (2001) · Neurology · doi:10.1212/wnl.57.8.1522-a · Cited by 10
Robertson, I. H., & Dockree, P. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108554350.010 · Cited by 10
Zuniga, N. R., Earls, N. E., Denos, A. E. A., Elison, J. M., Jones, B. S., Smith, E. G., Moran, N. G., Broce, K. L., Romero, G. M., Hyer, C. D., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012407 · Cited by 9
Triumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Weber, C. M., Moiz, B., Pena, G. S., Kheradmand, M., Wunderler, B., Kettula, C., Sangha, G. S., Smith, J. C., & Clyne, A. M. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105487 · Cited by 10
“In humans, the APOE-ε 4 genotype is correlated with many AD biomarkers, including increased blood – brain barrier (BBB) permeability, 5 decreased brain glucose metabolism, 6 and increased amyloid-β (A β ) and tau accumulation.”
Positron Emission Tomography for Neurologists
Miletich, R. S. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.004 · Cited by 13
Age-related mild cognitive deficit: a ready-to-use concept?
Gilles, C. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/cgilles · Cited by 10
“That functional imaging is able to detect preclinical AD is suggested by positron emission tomography (PET) studies, which found regional cerebral glucose metabolism (rCMRGlu) alterations in nondemented subjects at risk of AD (ie, those carrying the apolipoprotein E type 4 allele [ApoE ε4] and with familial history of…”
BackgroundFan, L., Zhu, X., Borenstein, A. R., Huang, X., Shrubsole, M. J., Dugan, L. L., & Dai, Q. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.37 · Cited by 9
“AD patients have been commonly characterized with impaired glucose uptake and cerebral hypometabolism in the brain monitored by 18 F-FDG PET, which is correlated with clinical cognitive decline and pathological progression of AD (54).”
PET en neurología y psiquiatría I. PET con FDG en el estudio del SNC
Andrée, R. M., Jiménez-Vicioso, A., Jáuregui, J. C., Aliño, J. J. L.-I., & Delgado, J. L. C. (2002) · Revista Española de Medicina Nuclear · doi:10.1016/s0212-6982(02)72110-1 · Cited by 9
Hatfield, B. D. (2008) · Quest · doi:10.1080/00336297.2008.10483575 · Cited by 9
“The team approach to exercise and the dementias by which the problem is approached at different levels of analysis also extends to technical issues (Small et al., 2000).”
BackgroundNeural underpinnings of background acoustic noise in normal aging and mild cognitive impairment
Sinanaj, I., Montandon, M., Rodriguez, C. K., Herrmann, F. R., Santini, F., Haller, S., & Giannakopoulos, P. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.031 · Cited by 8
Scavuzzo, C. J., LeBlancq, M. J., Nargang, F. E., Lemieux, H., Hamilton, T. J., & Dickson, C. T. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00370.2019 · Cited by 8
Matchar, D. B., Kulasingam, S., McCrory, D. C., Mb, P., Rutschmann, O. T., Samsa, G. P., & De, S. (2001) · Cited by 11
Classification of MRI and psychological testing data based on support vector machine.
Yang, W., Chen, X., Cohen, D. S., Rosin, E. R., Toga, A. W., Thompson, P. M., & Huang, X. (2017) · PubMed · Cited by 8
What Does Imaging Add to the Management of Alzheimer's Disease?
Small, G. W. (2004) · CNS Spectrums · doi:10.1017/s1092852900024779 · Cited by 8
“O4) in the frontal cortex, which is consistent with normal aging.(5) These two studies(2)'(5) provide evidence of biological degeneration despite intact neuropsychological function—a conclusion that could have great implications for dementia management.”
BackgroundSelf-citation‘Omics‘-Based Imaging in Cancer Detection and Therapy
Oehr, P. (2006) · Personalized Medicine · doi:10.2217/17410541.3.1.19 · Cited by 8
“Correspondingly, current neuroimaging studies suggest a possible influence of the APOE genotype on cerebral perfusion deficits, progression of atrophy, and decline of cerebral glucose metabolism in patients with AD [61,62].”
BackgroundCauses or consequences of inflammation and pathological signs of Alzheimer disease
Roses, A. D. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00142-1 · Cited by 8
Self-citationZádori, D., Zsolt, D., & Penke, B. (2007) · PubMed · Cited by 8
Chételat, G., Desgranges, B., Sayette, V. D. L., Viader, F., & Eustache, F. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)70944-3 · Cited by 10
Apolipoprotein E, Neurodegeneration, and Alzheimer Disease
Jagust, W. J. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.726 · Cited by 9
Biomolecular Markers of Brain Aging
Li, M., An, H., Wang, W., & Wei, D. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1627-6_9 · Cited by 9
HMGA1 deficiency: a pathogenic link between tau pathology and insulin resistance
Mirabelli, M., CHIEFARI, E. D., Arcidiacono, B., Salatino, A., Pascarella, A., Morelli, M., Credendino, S. C., Brunetti, F. S., Vito, A. D., Greco, A., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105700 · Cited by 8
“66 The neuron-speci fi c glucose transporter, GLUT3, is abundantly expressed in human and murine brain, and plays a crucial role in this process.”
Brain microvascular endothelial cell metabolism and its ties to barrier function
Weber, C. M., Moiz, B., & Clyne, A. M. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.05.002 · Cited by 9
Anglada‐Huguet, M., Endepols, H., Sydow, A., Hilgers, R., Neumaier, B., Drzezga, A. E., Kaniyappan, S., Mandelkow�, E., & Mandelkow, E.-M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119260 · Cited by 8
Attention and the Frontal Cortex
Cohen, R. A. (2013) · Springer eBooks · doi:10.1007/978-0-387-72639-7_13 · Cited by 7
Progress in neuroimaging of Alzheimer’s disease
Matsuda, H. (2007) · Psychogeriatrics · doi:10.1111/j.1479-8301.2007.00175.x · Cited by 8
Evolution and the Plasticity of Aging in the Reproductive Schedules in Long-Lived Animals
Finch, C. E. (2002) · Elsevier eBooks · doi:10.1016/b978-012532104-4/50081-0 · Cited by 9
La neuroimagen en la enfermedad de Alzheimer: perspectiva actual
Puche, J. C. M. (2004) · Revista de Neurología · doi:10.33588/rn.3812.2004291 · Cited by 8
Miichi, Y., Sakurai, T., Akisaki, T., & Yokono, K. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00712.x · Cited by 8
Evaluating dementia using PET: how do we put into clinical perspective what we know to date?
Silverman, D. H. S., & Phelps, M. E. (2000) · PubMed · Cited by 7
Self-citationPatil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 8
“Indeed, ApoE4 is strongly associated with decreased cerebral glucose metabolism in both AD patients and nondemented individuals [50,51].”
BackgroundFDG PET in the Evaluation of Mild Cognitive Impairment and Early Dementia
Mosconi, L., & Silverman, D. H. S. (2009) · Springer eBooks · doi:10.1007/978-0-387-76420-7_3 · Cited by 6
Self-citationLife-span influences of apoE4 on CNS function
Teter, B. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.028 · Cited by 6
The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly
Kollack‐Walker, S., Liu, C. Y., & Fleisher, A. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.010 · Cited by 6
Sarikaya, İ., Kamel, W. A., Ateyah, K., Essa, N., Altailji, S., & Sarıkaya, A. (2021) · World Journal of Nuclear Medicine · doi:10.4103/wjnm.wjnm_53_18 · Cited by 6
Imaging Genetics and Psychiatry
Kempf, L., & Meyer‐Lindenberg, A. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.3.327 · Cited by 9
Progress report on Alzheimer’s disease: Taking the next steps
(2000) · Ageing International · doi:10.1007/s12126-000-1003-0 · Cited by 10
Neuroimaging to predict preclinical Alzheimer's disease
Kumari, V., Mitterschiffthaler, M. T., & Sharma, T. (2002) · Hospital Medicine · doi:10.12968/hosp.2002.63.6.2004 · Cited by 6
Presymptomatic Signs in Healthy CJD Mutation Carriers
Gigi, A., Vakil, E., Kahana, E., & Hadar, U. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000084549 · Cited by 6
Silverman, D. H. S., & Small, G. W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1482 · Cited by 8
Self-citationRaskind, M. A., Wilkinson, C. W., & Peskind, E. R. (2002) · Elsevier eBooks · doi:10.1016/b978-012532104-4/50105-0 · Cited by 6
Borges, K. A., Lombardi, I., Sivilli, M., Aabye, J., Romano, I., Nasruddin, S. A., Padalkar, M. V., Moussouros, D., & Savinova, O. V. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1557625 · Cited by 5
Wang, W., Chen, Y., Xiong, Z., Wang, Z., Ye, W., & Li, X. (2026) · Brain and Behavior · doi:10.1002/brb3.71251 · Cited by 5
The Clinical Use of SPECT and PET Molecular Imaging in Alzheimer’s Disease
Valotassiou, V. J., Sifakis, N., Papatriantafyllou, J. D., Angelidis, G., & Georgoulias, P. (2011) · InTech eBooks · doi:10.5772/18825 · Cited by 6
“FDG PET studies in asymptomatic apolipoprotein ε4 allele (APOE e4) carriers demonstrated a decline of metabolism in the left posterior cingulated, inferior parietal, and lateral temporal regions (Kennedy et al., 1995; Small et al., 2000).”
BackgroundNeuroimaging of sleep disorders
Nofzinger, E. A., Maquet, P., & Thorpy, M. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088268.025 · Cited by 5
Liu, X., Zeng, Q., Luo, X., Li, K., Hong, H., Wang, S., Guan, X., Wu, J., Zhang, R., Zhang, T., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.591347 · Cited by 5
Disruption of Glucose Metabolism in Aged Octodon degus: A Sporadic Model of Alzheimer's Disease
Cisternas, P., Gherardelli, C., Salazar, P. L., & Inestrosa, N. C. (2021) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2021.733007 · Cited by 5
Human APOE ɛ3 and APOE ɛ4 Alleles Have Differential Effects on Mouse Olfactory Epithelium
Khan, N., Alimova, Y. V., Clark, S. J., Vekaria, H. J., Walsh, A. E., Williams, H. C., Hawk, G. S., Sullivan, P. G., Johnson, L. A., & McClintock, T. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215152 · Cited by 6
Balthazar, F. M., Moraes, W. A. D. S., Hunter, J., do Prado, G. F., & de Carvalho, L. B. C. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0042-1758399 · Cited by 5
Regional Quantitative Analysis of Cortical Surface Maps of FDG PET Images
Protas, H. D., Thompson, P. M., Hayashi, K., Yu, C.-L., Bergsneider, M., & Huang, S.-C. (2006) · IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC) · doi:10.1109/nssmic.2005.1596673 · Cited by 5
“It has been used to see regional metabolic decline in subjects with genetic risk for Alzheimer’s[2].”
Self-citationChen, K., Smilovici, Q., Lee, W., Reschke, C., Zhu, Z., Bandy, D. J., & Reiman, E. M. (2007) · ICME International Conference on Complex Medical Engineering (CME) · doi:10.1109/iccme.2007.4381871 · Cited by 5
“As '8F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)hasbecomemorereadily available, ithasbeenincreasingly usedtostudy various humanbrain diseases including Alzheimer dementia (AD) [1;2] andthegenetic risk ofAD associated withthepresence ofapolipoprotein £4[3- 7 ].”
BackgroundLipoprotein Genes and Diet in the Evolution of Human Intelligence and Longevity
Finch, C. E., & Stanford, C. B. (2003) · Springer eBooks · doi:10.1007/978-3-642-59356-7_3 · Cited by 5
O'Hara, R. M. (2005) · SLEEP · doi:10.1093/sleep/28.11.1355 · Cited by 5
Neuroimaging of Alzheimer’s Disease, Mild Cognitive Impairment, and Other Dementias
Risacher, S. L., & Saykin, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6373-4_19 · Cited by 5
Functional Neuroimaging Studies of Aging
Grady, C. L. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00103-0 · Cited by 7
Neuroimaging: Anything to do with neurotherapeutics?
Masdeu, J. C., & Bakshi, R. (2005) · NeuroRx · doi:10.1602/neurorx.2.2.163 · Cited by 6
Duffy, J. S., Ainslie, P. N., Rasmussen, P., MacLeod, D. B., & Gibbons, T. D. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251399122 · Cited by 5
“Likewise, 15 O-PET can be used to calculate regional and global measures of oxygen consumption via the infusion of [ 15 O]O 2 , a radioisotope of oxygen.”
Recent developments in translational imaging of in vivo gene therapy outcomes
Day, I. L., Tamboline, M., Lipshutz, G. S., & Xu, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.049 · Cited by 5
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.